Aromasin may cause damage to developing embryos. You should use an effective non-hormonal type of birth control — such as condoms, a diaphragm along with spermicide, or a non-hormonal I. Ask your doctor which type of non-hormonal birth control would be best for you, as well as how long you should use this type of birth control after you stop taking Aromasin.
The large IES Intergroup Exemestane Study trial was started in and compared switching to Aromasin after taking tamoxifen for 2 to 3 years to staying on tamoxifen for 5 years. The results have shown that switching to Aromasin for 2 to 3 years AFTER taking tamoxifen 2 to 3 years for a total of 5 years of hormonal therapy medicine was better than staying on tamoxifen for 5 years for:.
Research published in showed that Aromasin can lower risk in high-risk, postmenopausal women who've never been diagnosed with breast cancer. Aromasin is not approved by the FDA for this use, but doctors may consider it a good alternative to tamoxifen or Evista. In , the American Society of Clinical Oncology ASCO released new guidelines on using hormonal therapy medicines to reduce breast cancer risk in high-risk women. These guidelines recommend that doctors talk to high-risk postmenopausal women about using Aromasin to reduce risk.
ASCO is a national organization of oncologists and other cancer care providers. ASCO guidelines give doctors recommendations for treatments that are supported by much credible research and experience. Because Aromasin lowers the amount of estrogen in the body, less estrogen reaches bone cells, which can lead to bone thinning and weakening and a higher-than-average risk of broken bones.
This side effect can be very troubling for some women. If you have osteoporosis , your doctor may recommend that you take tamoxifen rather than Aromasin because of this possible side effect. Some side effects may mean that you're having an allergic reaction to Aromasin. At the last report of the trial at ECCO 10 in Vienna, the median overall survival for the megestrol acetate group was Jones said, the median has not been reached for patients treated with exemestane.
For the exemestane group, it was The time to tumor progression, however, was significantly longer with use of exemestane, Dr. Jones said, a median of 4. Further, the duration of response was significantly longer with exemestane In earlier trials, exemestane was tested as second- and third-line therapy.
Jones said. It acts as a false substrate for the aromatase enzyme and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its inactivation. Exemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has no detectable effect on adrenal biosynthesis of corticosteroids or aldosterone. FDA Label. Lundbeck Takeda Pharmaceuticals U.
Aromasin Tablets Profile. Profile Contact Information. Currently Enrolling Trials Show More. General Information Aromasin, a new drug to treat post-menopausal advanced breast cancer in patients for whom treatment with tamofixen was ineffective, has been shown to inhibit the production of estrogen, upon which some breast cancer cells depend.
Aromasin has not yet been tested for pediatric patients. Clinical Results A phase III, double blind, randomized study was conducted for post-menopausal patients whose breast cancer had metastasized spread.
0コメント